On 30 January, in a significant step forward in Europe’s ability to respond swiftly to future health crises, Bilthoven Biologicals (BBio), member of the EUFab network, officially inaugurated its new pandemic preparedness manufacturing facilities. Hosted at Bilthoven Science Park and completed in just 12 months, the facilities reinforce Europe’s strategic health autonomy by bolstering vaccine manufacturing capacity and supporting EU-wide pandemic response efforts.
The facilities are equipped with cutting-edge drug substance (bulk antigen) purification, and fill/finish isolator technologies, enabling the efficient and rapid production of critical vector-based vaccines. Designed for multi-product manufacturing, the site has the capability to produce up to 300 million doses of vaccines per year and monoclonal antibodies. This expansion strengthens Europe’s preparedness for future health emergencies, contributing to a more resilient and responsive vaccine manufacturing infrastructure.
As part of its core mandate, HERA remains steadfast in its commitment to ensuring equal access to medical countermeasures for all European citizens. Looking ahead, one of HERA’s top priorities this year is the development of a new EU Strategy on Medical Countermeasures to leverage key tools such as joint procurements, stockpiling, and innovative financial instruments, ensuring a comprehensive approach to tackling emerging health threats. With risks ranging from antimicrobial resistance and chemical, biological, radiological, and nuclear (CBRN) threats to the impact of climate change, strengthening Europe’s resilience and readiness remains at the heart of HERA’s mission.
More here.